健康去哪儿
健趣网登录 关闭
还没有账号?立即注册

Patient Pathway Pharmacist - Optimal Drug-related Care

Sponsor:
Collaborators:
Information provided by (Responsible Party):
Ben Tore Henriksen,Sykehuset i Vestfold HF
September 11, 2018
October 3, 2018
October 3, 2018
September 3, 2018
February 15, 2019   (Final data collection date for primary outcome measure)
Discharge summary score[ Time Frame: At discharge (estimated five days after fracture/inclusion) ]
In the discharge summary, the section describing drugs is scored in accordance with the national patient safety program

Admission summary score[ Time Frame: At hospital admission (estimated to be within 24 hours after fracture) ]
In the admission summary, the section describing drugs is scored. The score is adjusted from the discharge summary score to fit the admission note.

Discharge summaries written in accordance with procedure[ Time Frame: At discharge (estimated five days after fracture/inclusion) ]
In the discharge summary, the section describing drugs should be in accordance with procedure.

Number of inappropriate drugs at discharge[ Time Frame: During hospitalisation, after surgery (estimated to be within five days after fracture/inclusion) ]
After surgery the medication review may reduce the number of inappropriate drugs (on the STOPP-list).

Same as current
  • Readmission[ Time Frame: 30 days after discharge ]
    Patients who are readmitted to hospital is quantified
  • Readmission[ Time Frame: 90 days after discharge ]
    Patients who are readmitted to hospital is quantified
  • Death[ Time Frame: 30 days after discharge ]
    The number patients who dies is quantified
  • Death[ Time Frame: 90 days after discharge ]
    The number of patients who dies is quantified
 

Patient Pathway Pharmacist - Optimal Drug-related Care

Patient Pathway Pharmacist: Drug Optimisation for Hip Fracture Patients - Facilitating a Safe Patient Handover: a Descriptive Study

Medication errors represent the most common cause of patient injury and one of the most frequently reported health related deviation in Norway. The addition of a dedicated clinical pharmacist throughout the hip fracture patient pathway (patient pathway pharmacist) is believed to improve patient safety and ensure optimal drug-related patient care. The pharmacist will perform medication reconciliation at admission to hospital, medication review after surgery and assist physicians with discharge summary. Six weeks after discharge the patient pathway pharmacist will perform a second drug reconciliation and medication review. This study will assess the pharmacists' place and specific tasks in the patient pathway, describe areas where the pharmacist contribute to increased quality of care and assess the benefits and/or disadvantages experienced with introducing a patient pathway pharmacist. The estimated number of patients included is 60. Current practice will be determined by investigating the last 50 patients' medical record and a questionnaire to health care professionals involved in treatment of hip fracture patients. Data from medication reconciliation and drug review will be collected and compared to current practice. After the inclusion period, focus group surveys and/or semi-structured interviews will be executed to describe the perceived improvement in the quality of care. Primary endpoints are: 1) Medication reconciliation score at admission 2) Number of inappropriate drugs for elderly 3) Discharge summary score 4) Discharge summaries following procedure. Secondary endpoints are readmissions and mortality after 30 and 90 days. Qualitative endpoints: 1) Health care professionals experience of current drug-related practice 2) Experienced advantages and disadvantages of a patient pathway pharmacist.

Interventional
N/A
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: An intervention group is compared to a cross-sectional retrospective group. A group of 60 patients with hip fracture will get an intervention by a clinical pharmacist who performs medication reconciliation and medication review during hospitalisation, they will receive a discharge summary where the medication part is optimised. After six weeks the patients will be get a follow-up with a second medication reconciliation and - review. This group will be compared with the last 50 patients with hip fracture who did not get the intervention.
Masking: Interventional
Masking Description:
Primary Purpose: Supportive Care
  • Procedure: Patient Pathway Pharmacist intervention
    Medication reconciliation at admission to hospital Medication review post surgery Optimised list of drugs in the discharge summary, in accordance with hospital procedures Medication reconciliation, six weeks after discharge Medication review, six weeks after discharge
  • Experimental: Patient Pathway Pharmacist intervention
    Medication reconciliation at admission to hospital Medication review post surgery Optimised list of drugs in the discharge summary, in accordance with hospital procedures Medication reconciliation, six weeks after discharge Medication review, six weeks after discharge
  • No Intervention: No intervention
    Business as usual. The Patient Pathway Pharmacist is not involved and the nurses and physicians are responsible for medicine reconciliation, -review and section in the discharge summary.
 
Recruiting
60
Same as current
March 30, 2019
February 15, 2019   (Final data collection date for primary outcome measure)
Inclusion Criteria: - Hip fracture patients in Vestfold county, Norway Exclusion Criteria: - Patients under 18 years - Terminally ill - Hip fracture patients who do not follow the standardized patient pathway at Vestfold Regional Hospital - Patients who do not consent to be included in the study
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Norway
 
 
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Ben Tore Henriksen,Sykehuset i Vestfold HF
Sykehuset i Vestfold HF
:
Sykehuset i Vestfold HF
October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
请使用微信扫码报名